Vasopressin tannate
Pitressin (vasopressin tannate) is a protein pharmaceutical. Vasopressin tannate was first approved as Pitressin tannate on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vasopressin tannate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PITRESSIN TANNATE | Pfizer | N-003402 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
311 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 5 | 5 | 22 | 30 | 7 | 68 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 7 | 2 | 3 | 7 | 9 | 27 |
| Healthy volunteers/patients | — | 17 | — | — | 3 | — | 20 | ||
| Schizophrenia | D012559 | EFO_0000692 | F20 | 2 | 1 | 2 | 5 | 2 | 12 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 3 | 3 | 1 | 1 | 7 |
| Dementia | D003704 | F03 | 1 | — | 2 | 2 | — | 5 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 1 | 1 | 2 | — | 5 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | 3 | 1 | 1 | — | 5 |
| Glioma | D005910 | EFO_0000520 | 1 | 2 | — | 1 | — | 4 | |
| Mania | D000087122 | F30 | — | — | — | 4 | — | 4 |
Show 26 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Seizures | D012640 | G40.4 | 1 | — | 3 | — | 2 | 6 | |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | 5 | — | — | 6 |
| Glioblastoma | D005909 | EFO_0000515 | 2 | 2 | 1 | — | — | 5 | |
| Status epilepticus | D013226 | EFO_0008526 | G41 | — | 2 | 1 | — | 2 | 5 |
| Spinal muscular atrophy | D009134 | EFO_0008525 | G12.1 | 1 | 2 | 1 | — | — | 4 |
| Astrocytoma | D001254 | EFO_0000271 | 1 | 1 | 1 | — | — | 3 | |
| Diffuse intrinsic pontine glioma | D000080443 | — | 1 | 1 | — | — | 2 | ||
| Neuroepithelial neoplasms | D018302 | — | 1 | 1 | — | — | 2 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | 1 | — | — | 2 |
| Uterine cervical neoplasms | D002583 | — | 1 | 1 | — | — | 2 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 13 | 2 | — | — | — | 14 | |
| Myelodysplastic syndromes | D009190 | D46 | 2 | 8 | — | — | — | 9 | |
| Myeloid leukemia acute | D015470 | C92.0 | 4 | 8 | — | — | — | 9 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 3 | 2 | — | — | 1 | 5 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 3 | — | — | — | 5 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 3 | 1 | — | — | — | 4 |
| Leukemia | D007938 | C95 | 1 | 3 | — | — | — | 3 | |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 2 | — | — | 1 | 3 |
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | 1 | — | — | — | 2 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 2 | 1 | — | — | — | 2 |
Show 40 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | 3 | — | — | — | 1 | 4 | ||
| Drug interactions | D004347 | 3 | — | — | — | — | 3 | ||
| Nasopharyngeal neoplasms | D009303 | 2 | — | — | — | — | 2 | ||
| Central nervous system neoplasms | D016543 | 2 | — | — | — | — | 2 | ||
| Traumatic brain injuries | D000070642 | S06 | 1 | — | — | — | 1 | 2 | |
| Hemorrhagic shock | D012771 | 2 | — | — | — | — | 2 | ||
| Mantle-cell lymphoma | D020522 | C83.1 | 1 | — | — | — | — | 1 | |
| Burkitt lymphoma | D002051 | C83.7 | 1 | — | — | — | — | 1 | |
| Non-small-cell lung carcinoma | D002289 | 1 | — | — | — | — | 1 | ||
| Urologic neoplasms | D014571 | C64-C68 | 1 | — | — | — | — | 1 |
Show 20 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 1 | 1 |
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | — | 1 | 1 | |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
| Body composition | D001823 | — | — | — | — | 1 | 1 | ||
| Alveolar bone loss | D016301 | — | — | — | — | 1 | 1 | ||
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | — | — | 1 | 1 |
| Nocturnal enuresis | D053206 | N39.44 | — | — | — | — | 1 | 1 | |
| Borderline personality disorder | D001883 | HP_0012076 | F60.3 | — | — | — | — | 1 | 1 |
| Cluster headache | D003027 | HP_0012199 | G44.00 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VASOPRESSIN TANNATE |
| INN | vasopressin injection |
| Description | Argipressin is the predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. It has a role as a cardiovascular drug, a hematologic agent and a mitogen. It is a conjugate base of an argipressin(2+). |
| Classification | Protein |
| Drug class | vasoconstrictors (vasopressin derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 103529-95-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201528 |
| ChEBI ID | — |
| PubChem CID | 644077 |
| DrugBank | DB00067 |
| UNII ID | Y87Y826H08 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,050 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
22,449 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more